Clinical case of statin-induced myopathy in female patient with compensated hypothyroidism and unfavorable polymorphic variant of SLCO1B1*5 (c.521T>C)

Liya A. Lugovaya , Alexey A. Nekrasov , Leonid G. Strongin , Tatyana A. Nekrasova

For citation:

Abstract

Statin-associated muscle symptoms are one of the statin-induced side effects. The incidence of the condition is increased by the presence of associated risk factors, one of which is hypothyroidism. The paper reports clinical case of statin-associated muscle symptoms in patient with compensated hypothyroidism carrying a SLCO1B1 mutation. Optimal assessment and treatment algorithms are discussed.

Key words: compensated hypothyroidism, statins, myopathy, SLCO1B1.

References

1. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VII peresmotr. Ateroskleroz i dislipidemii. 2020; 1 (38): 7–42. DOI: 10.34687/2219-8202.JAD.2020.01.0002 (in Russian).

2. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019. DOI: 10.1093/eurheartj/ehz455

3. Tuteja S, Rader DJ. SLCO1B1 and Statin Therapy. Circulation: Genom Precision Med 2018; 11: e002320. DOI: 10.1161/CIRCGEN. 118.002320

4. Ezhov M.V., Sergienko I.V., Aronov D.M et al. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Ateroskleroz i dislipidemii. 2017; 3: 5–22 (in Russian).

5. Muntean DM, Thompson PD, Catapano AL et al. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today 2017; 22: 85–96.

6. Toth PP, Patti AM, Giglio RV et al; Maciej Banach. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs 2018; 18 (3): 157–73. DOI: 10.1007/s40256-017-0259-7

7. Chu Ch-Sh, Tseng P-T, Stubbs B et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Sci Rep 2018; 8: 5804. DOI: 10.1038/s41598-018-24248-8

8. Turongkaravee S, Jittikoon J, Lukkunaprasit T et al. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J 2021. DOI: 10.1038/s41397-021-00208w

9. Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403–14.

10. Cohen JD, Brinton EA, Ito MK et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6: 208–15.

11. Adhyaru BB, Jacobson TA. Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins. Evid Based Med 2017; 22 (6): 210. DOI: 10.1136/ebmed-2017-110783

12. Kukharchuk V.V., Arabidze G.G., Balakhonova T.V. et al. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Evraziiskaia assotsiatsiia kardiologov. Natsional'noe obshchestvo po izucheniiu ateroskleroza (NOA). Moscow, 2020 (in Russian).

13. Stroes ES, Thompson PD, Corsini A et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012–22. DOI: 10.1093/eurheartj/ ehv043

14. Commentary SAMS: Statin-Associated Muscle Symptoms – Update 2017. https://www.eas-society.org/page/update_sams_paper

15. Kajinami K, Tsukamoto K, Koba Sh et al. Statin Intolerance Clinical Guide 2018. J Atheroscler Thromb 2020; 27 (4): 375–96. DOI: 10.5551/jat.50948

16. Qari FA. Severe rhabdomyolysis and acute renal failure secondary to use of simvastatin in undiagnosed hypothyroidism. Saudi J Kidney Dis Transpl 2009; 20 (1): 127–9.

17. Ambapkar SN et al. Statin-induced rhabdomyolysis in patient with renal failure and underlying undiagnosed hypothyroidism. Indian J Crit Care Med 2016; 20 (5): 305–7.

18. Lugovaia L.A. Kliniko-laboratornye priznaki porazheniia myshts u bol'nykh kompensirovannym gipotireozom na fone lecheniia statinami.: dis. … kand. med. nauk. Nizhnii Novgorod, 2018 (in Russian).

19. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158 (3): 693–705. DOI: 10.1111/j.1476-5381.2009.00430.x

20. SLCO1B1 variants and statin-induced myopathy – a genomewide study. Search Collaborative Group. The N Engl J Med 2008; 359 (8): 789–99.

21. Kitzmiller JP et al. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmaco Personalized Medicine 2016: 9: 97–106. DOI: 10.2147/PGPM.S86013

22. Ramsey LB, Johnson SG, Caudle KE et al. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014; 96 (4): 423–8.

23. DeGorter MK, Tirona RG, Schwarz UI et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 2013; 6 (4): 400–4.

24. Ridker PM, Danielson E, Fonseca FAH et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.

25. Rosenson RR, Baker S., Banach et al. Optimizing Cholesterol Treatment in Patient With Muscle Complaints. J Am CollCardiol 2017; 70: 1290–301.

For citation:Lugovaya L.A., Nekrasov A.A., Strongin L.G., Nekrasova T.A. Clinical case of statin-induced myopathy in female patient with compensated hypothyroidism and unfavorable polymorphic variant of SLCO1B1*5 (c.521T>C). Clinical review for general practice. 2021; 5: 21–24. DOI: 10.47407/kr2021.2.5.00066

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice